Interacciones de Ganciclovir
Ganciclovir (Cytovene, Zirgan), antiviral, tiene 26 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 3; moderadas: 21; leves: 2; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.
Interacciones según la etiqueta
Interacciones graves (3)
…Significant Drug Interactions with Ganciclovir for Injection Name of the Concomitant Drug Change in the Concentration of Ganciclovir or Concomitant Drug Clinical Comment Imipenem-cilastatin Unknown Coadministration with imipenem-cilastatin is not recommended because generalized seizures have been reported in patients who received ganciclovir and imipenem-cilastatin. (etiqueta de Ganciclovir, Interacciones medicamentosas)
…Nucleoside analogues, e.g., ribavirin Hematologic/Bone Marrow Suppressive/Cytotoxic Agents Coadministration with the following drugs may increase the hematologic toxicity of zidovudine: • Ganciclovir • Interferon alfa • Ribavirin • Other bone marrow suppressive or cytotoxic agents 7.2 Lamivudine Sorbitol Coadministration of single doses of lamivudine and sorbitol resulted… (etiqueta de Lamivudina y zidovudina, Interacciones medicamentosas)
Ganciclovir for Injection is contraindicated in patients who have experienced a clinically significant hypersensitivity reaction (e.g., anaphylaxis) to ganciclovir, valganciclovir, or any component of the formulation. (etiqueta de Ganciclovir, Contraindicaciones)
Interacciones moderadas (21)
Increased serum creatinine levels have been reported in elderly patients and in transplant recipients receiving concomitant nephrotoxic medications (i.e., cyclosporine and amphotericin B). (etiqueta de Ganciclovir, Advertencias y precauciones)
Increased serum creatinine levels have been reported in elderly patients and in transplant recipients receiving concomitant nephrotoxic medications (i.e., cyclosporine and amphotericin B). (etiqueta de Ganciclovir, Advertencias y precauciones)
- DapsonaModerada
Other drugs associated with myelosuppression or nephrotoxicity (e.g., dapsone, doxorubicin, flucytosine, hydroxyurea, pentamidine, tacrolimus, trimethoprim/ sulfamethoxazole, vinblastine, vincristine and zidovudine) Unknown Because of potential for higher toxicity, coadministration with Ganciclovir should be considered only if the potential benefits are judged… (etiqueta de Ganciclovir, Interacciones medicamentosas)
- DoxorubicinaModerada
Other drugs associated with myelosuppression or nephrotoxicity (e.g., dapsone, doxorubicin, flucytosine, hydroxyurea, pentamidine, tacrolimus, trimethoprim/ sulfamethoxazole, vinblastine, vincristine and zidovudine) Unknown Because of potential for higher toxicity, coadministration with Ganciclovir should be considered only if the potential benefits are judged… (etiqueta de Ganciclovir, Interacciones medicamentosas)
Some examples include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] . (etiqueta de Efavirenz, lamivudina y tenofovir, Interacciones medicamentosas)
Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] . (etiqueta de Elvitegravir, cobicistat, emtricitabina y tenofovir, Interacciones medicamentosas)
Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] . (etiqueta de Emtricitabina y tenofovir, Interacciones medicamentosas)
Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, adefovir dipivoxil, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.5) ] . (etiqueta de Emtricitabina, rilpivirina y tenofovir, Interacciones medicamentosas)
Other drugs associated with myelosuppression or nephrotoxicity (e.g., dapsone, doxorubicin, flucytosine, hydroxyurea, pentamidine, tacrolimus, trimethoprim/ sulfamethoxazole, vinblastine, vincristine and zidovudine) Unknown Because of potential for higher toxicity, coadministration with Ganciclovir should be considered only if the potential benefits are judged… (etiqueta de Ganciclovir, Interacciones medicamentosas)
Other drugs associated with myelosuppression or nephrotoxicity (e.g., dapsone, doxorubicin, flucytosine, hydroxyurea, pentamidine, tacrolimus, trimethoprim/ sulfamethoxazole, vinblastine, vincristine and zidovudine) Unknown Because of potential for higher toxicity, coadministration with Ganciclovir should be considered only if the potential benefits are judged… (etiqueta de Ganciclovir, Interacciones medicamentosas)
Mycophenolate mofetil (MMF) ↔ Ganciclovir (in patients with normal renal function) ↔ MMF (in patients with normal renal function) Based on increased risk, patients should be monitored for hematological and renal toxicity. (etiqueta de Ganciclovir, Interacciones medicamentosas)
OAT1/OAT3 Substrates (e.g., adefovir, ganciclovir, methotrexate) Clinical Impact Increased exposure of the interacting drug. [see Clinical Pharmacology ( 12.3 )] Prevention or Management Monitor for potential adverse reactions related to the co-administered drug. (etiqueta de Nitisinona, Interacciones medicamentosas)
Other drugs associated with myelosuppression or nephrotoxicity (e.g., dapsone, doxorubicin, flucytosine, hydroxyurea, pentamidine, tacrolimus, trimethoprim/ sulfamethoxazole, vinblastine, vincristine and zidovudine) Unknown Because of potential for higher toxicity, coadministration with Ganciclovir should be considered only if the potential benefits are judged… (etiqueta de Ganciclovir, Interacciones medicamentosas)
- ProbenecidModerada
Probenecid ↑Ganciclovir Ganciclovir for Injection dose may need to be reduced. (etiqueta de Ganciclovir, Interacciones medicamentosas)
- Probenecid y colchicinaModerada
Probenecid ↑Ganciclovir Ganciclovir for Injection dose may need to be reduced. (etiqueta de Ganciclovir, Interacciones medicamentosas)
Other drugs associated with myelosuppression or nephrotoxicity (e.g., dapsone, doxorubicin, flucytosine, hydroxyurea, pentamidine, tacrolimus, trimethoprim/ sulfamethoxazole, vinblastine, vincristine and zidovudine) Unknown Because of potential for higher toxicity, coadministration with Ganciclovir should be considered only if the potential benefits are judged… (etiqueta de Ganciclovir, Interacciones medicamentosas)
Other drugs associated with myelosuppression or nephrotoxicity (e.g., dapsone, doxorubicin, flucytosine, hydroxyurea, pentamidine, tacrolimus, trimethoprim/ sulfamethoxazole, vinblastine, vincristine and zidovudine) Unknown Because of potential for higher toxicity, coadministration with Ganciclovir should be considered only if the potential benefits are judged… (etiqueta de Ganciclovir, Interacciones medicamentosas)
Some examples include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.2) ]. (etiqueta de Tenofovir, Interacciones medicamentosas)
Other drugs associated with myelosuppression or nephrotoxicity (e.g., dapsone, doxorubicin, flucytosine, hydroxyurea, pentamidine, tacrolimus, trimethoprim/ sulfamethoxazole, vinblastine, vincristine and zidovudine) Unknown Because of potential for higher toxicity, coadministration with Ganciclovir should be considered only if the potential benefits are judged… (etiqueta de Ganciclovir, Interacciones medicamentosas)
- VincristinaModerada
…drugs associated with myelosuppression or nephrotoxicity (e.g., dapsone, doxorubicin, flucytosine, hydroxyurea, pentamidine, tacrolimus, trimethoprim/ sulfamethoxazole, vinblastine, vincristine and zidovudine) Unknown Because of potential for higher toxicity, coadministration with Ganciclovir should be considered only if the potential benefits are judged to outweigh… (etiqueta de Ganciclovir, Interacciones medicamentosas)
…with myelosuppression or nephrotoxicity (e.g., dapsone, doxorubicin, flucytosine, hydroxyurea, pentamidine, tacrolimus, trimethoprim/ sulfamethoxazole, vinblastine, vincristine and zidovudine) Unknown Because of potential for higher toxicity, coadministration with Ganciclovir should be considered only if the potential benefits are judged to outweigh the risks. (etiqueta de Ganciclovir, Interacciones medicamentosas)
Menciones leves (2)
Initiate therapeutic ganciclovir (or equivalent) for CMV infection or confirmed CMV viremia. (etiqueta de Alemtuzumab, Advertencias y precauciones)
- RomidepsinaLeve
Reactivation of Epstein Barr viral infection leading to liver failure has occurred in recipients of ISTODAX including after ganciclovir prophylaxis. (etiqueta de Romidepsina, Advertencias y precauciones)
Compruebe Ganciclovir frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.
Abrir en el verificadorNo es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.